Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.

DUPLEX, the largest interventional FSGS trial to date, enrolled 371 biopsy-proven or genetically defined FSGS patients to test the dual endothelin–angiotensin receptor antagonist sparsentan against irbesartan, establishing a geographically and clinically diverse baseline population.